Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 1000 MBq/mL [27 mCi/mL]) |
| Drug Class | Radioligand therapeutic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Lutetium-177-PSMA-617 is indicated for patients with metastatic castrate-resistant prostate cancer (mCRPC) following the failure of novel anti-androgen therapy and chemotherapy, but specific effectiveness metrics (e.g., survival rates) are not detailed.
- The abstract does not provide detailed comparative effectiveness data, though it implies Lutetium-177-PSMA-617 is considered after other treatments fail.
- No effectiveness data are provided for specific population subgroups within the mCRPC patient population.
- No specific safety concerns or adverse effects are mentioned, and further details are needed for a comprehensive safety evaluation.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Prescribing Information. | 2022 | Advanced Accelerator Applications USA, Inc., Millburn, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review | 2023 | Expert Review of Anticancer Therapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy. | 2023 | Health Physics |